Evolution of the Average Target: AstraZeneca PLC

Evolution of the Average Target - AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Evolution of the Target Price - AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

6f11bc3a5850c.rJhrqk-eJkLVjc47r2La6unYWJA_Zx7FWh-6i0FqdJ0.5e4mxiSsaQeBtZRx6FSQ05O0Fql-JXOGIGrLyhEaMa709AfCEP1UG4bFmw~fceac42d00d9ae167a3f9148b66bf0d2
10-07 Berenberg Trims AstraZeneca PT, Affirms Outperform Rating MT
10-07 Deutsche Bank ups Glencore, BHP price targets AN
10-07 AstraZeneca PLC : Buy rating from Berenberg ZD
10-07 AstraZeneca PLC : Jefferies gives a Buy rating ZD
10-07 AstraZeneca PLC : Bernstein reaffirms its Buy rating ZD
10-06 Genmab in Good Health, Schneider Lacks Energy Zonebourse
10-06 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
09-30 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
09-29 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
09-29 Stocks Defy the Pressure Zonebourse
09-29 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
09-29 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
09-29 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD
09-29 AstraZeneca PLC : Deutsche Bank is Neutral ZD
09-18 Berenberg and Deutsche say buy Bytes Technology AN
09-16 AstraZeneca PLC : Gets a Buy rating from UBS ZD
09-16 Oddo BHF cuts Safestore to neutral, cuts target AN
09-16 AstraZeneca PLC : Buy rating from Jefferies ZD
09-16 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
09-16 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
09-15 Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says MT
09-15 Deutsche Bank Upgrades AstraZeneca to Hold, Lifts PT MT
09-15 Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating MT
09-15 Berenberg Maintains AstraZeneca at Buy as Pipeline Success Offsets Recent Setbacks; Price Target Down MT
09-15 Berenberg likes GSK; Deutsche Bank lifts Astra AN

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+33.32%
+13.74%
+9.03%
+3.33%
+10.46%
+6.66%
+6.54%
-3.33%
+8.35%
+22.38%
Average +11.05%
Weighted average by Cap. +10.69%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
157.15USD
Average target price
209.37USD
Spread / Average Target
+33.23%
High Price Target
262.96USD
Spread / Highest target
+67.34%
Low Price Target
157.72USD
Spread / Lowest Target
+0.36%

Analyst Consensus Detail

Analyst consensus - AstraZeneca PLC

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AstraZeneca PLC
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - AstraZeneca PLC
  1. Stock Market
  2. Stocks
  3. AZN Stock
  4. Consensus AstraZeneca PLC